Thu, May 7, 4:23 PM
- Nuance (NASDAQ:NUAN) uses its FQ2 report to state it's adding $500M to its buyback, bringing its total aurhorization to $591.7M. $120.3M was spent in FQ2 to buy back 8.56M shares at an average price of $14.06.
- The company guided in its prepared remarks (.pdf) for FY15 (ends Sep. '15) revenue of $1.94B-$1.98B and EPS of $1.13-$1.23; the former is unfavorable to a $1.98B consensus, but the latter is above a $1.12 consensus. FQ3 guidance is for revenue of $468M-$482M and EPS of $0.25-$0.29, mostly below a consensus of $487.7M and $0.28.
- FY15 net new bookings growth guidance has been cut to 1%-4% from a prior 4%-5%. A strong dollar is now expected to have a $55M impact on FY15 revenue ($10M worse than previously forecast), and a $32M impact on net new bookings.
- Net new bookings fell 27% Y/Y in FQ2 to $304.7M, thanks largely to a $100M connected car deal booked a year ago. However, the deferred revenue balance rose 26.3% Y/Y to $637.8M.
- Healthcare revenue (47% of total revenue) -4% Y/Y; mobile/consumer +9%, enterprise -7%; imaging -7%. In addition to buybacks, EPS got a lift from a 7% Y/Y drop in GAAP operating expenses to $245.3M.
- Nuance has risen to $15.82 AH.
- FQ2 results, PR
Thu, May 7, 4:04 PM| 10 Comments
Thu, Apr. 23, 2:28 PM
- Nuance (NASDAQ:NUAN) is sharply higher on volume of 2.19M shares (above a 3-month daily average of 1.89M). Shares (largely range-bound this year) have risen to their highest levels since December.
- Earlier today, the voice recognition software/services provider announced its FQ2 (calendar Q1) report would arrive on May 7. With Nuance having provided light guidance in February (thanks in part to soft mobile/consumer demand), expectations are low.
Tue, Apr. 14, 12:13 AM
- Nuance (NASDAQ:NUAN) has used this year's HIMSS health IT conference to unveil PowerMic Mobile, an app that lets physicians dictate and edit electronic health records (EHRs) by using iOS/Android phones that automatically pair with workstations running Nuance's Dragon Medical 360 voice recognition software. The app, which will be offered in May via subscription, eliminates the need for dedicated USB microphones.
- Also announced: 1) Solutions (test cases at this point) that let PowerMic Mobile dictate using Samsung's Gear S smartwatch, and for using Nuance's Florence healthcare mobile assistant with the Gear S. 2) A partnership with medical tech firms IMO and Meditech to create an offering that extracts structured data from physician notes and automatically creates patient problem lists and allergy lists.
- Though the company's consumer-facing products get more ink, Nuance's healthcare ops still accounted for 47% of the company's FQ1 (December quarter) revenue, and 58% of its op. profit. Organic growth was flat Y/Y, with Dragon Medical, diagnostics software, and Clintegrity growth offset by declining demand for traditional dictation offerings.
Thu, Mar. 19, 1:09 PM
- As part of a broader transfer of coverage for healthcare tech names, Baird has upgraded Cerner (CERN +3.3%) to Outperform, and hiked its target by $12 to $77. Allscripts (MDRX +3.6%) has been launched at Outperform, and assigned a $16 target. Quality Systems (QSII -1.1%) has been downgraded to Neutral.
- Also: Allscripts has announced it's partnering with healthcare voice recognition software vendor NoteSwift to resell NoteSwift's offerings with Allscripts' Professional EHR health record software, in response to customer demand. Nuance's (NASDAQ:NUAN) Dragon Medical powers NoteSwift's software.
- Cerner has made new highs. RBC downgraded Quality Systems last week.
Thu, Feb. 5, 5:35 PM
- Though it beat FQ1 estimates, Nuance (NASDAQ:NUAN) has guided in its prepared remarks (.pdf) for FQ2 revenue of $459M-$475M and EPS of $0.22-$0.26, below a consensus of $499.5M and $0.27. FY15 (ends Sep. '15) guidance is for revenue of $1.907B-$1.957B and EPS of $1.08-$1.18; the latter is in-line with a $1.13 consensus, but the former is below a $2.05B consensus.
- Net new bookings (excludes renewal bookings) fell 5.5% Y/Y in FQ1 to $303.8M. Nuance calls the 15 net new bookings it recorded "disappointing," and (thanks in part to forex) is lowering its FY15 net new bookings growth guidance to 4%-5% from 6%-8%.
- Thanks to the shift towards cloud/subscription revenue streams, the deferred revenue balance rose 28.2% to $484.3M. On-demand solutions made up 36% of revenue.
- Healthcare organic revenue growth was flat, mobile/consumer was -5%, enterprise -4%, and imaging -9%. Total organic growth was -3%. GAAP operating expenses rose by less than $300K Y/Y to $278.2M.
- Regarding mobile/consumer, Nuance notes mobile cloud transactions rose 66% Y/Y to 3.98B. But it also cautions it has "experienced pressure in the mobile phone industry as market share shifts among leading vendors and emerging companies, largely from China."
- FQ1 results, PR
Thu, Feb. 5, 4:04 PM| 5 Comments
Wed, Feb. 4, 5:35 PM
- ACET, ACLS, ADNC, AHL, AIV, ARCW, ASEI, ASYS, ATHN, ATR, ATVI, BCOV, BEBE, BMI, BRKS, BRS, BWLD, CALD, CME, CPST, CTRL, CUTR, DCT, DV, ECHO, ECOM, EGAN, EGOV, ENH, EXPE, FLDM, FLT, FWM, GPRO, HME, IMPV, KIM, KRG, LF, LGF, LNKD, MCK, MRIN, MTD, MXWL, NTGR, NUAN, OLN, ONNN, OUTR, P, PCTY, PDFS, PDM, PXLW, RDEN, RENT, SIMG, SLH, SPF, SPSC, SRCL, SWIR, SYMC, TPX, TSYS, TWTR, UBNT, UEPS, VRSN, WAIR, YELP, YRCW
Mon, Jan. 26, 2:23 PM| 5 Comments
Mon, Jan. 12, 2:21 PM
- Asian Sweeper speculates Baidu could make a bid for Nuance (NUAN +1%), given its strong interest in voice recognition. "Building an organic solution would take time, but acquiring Nuance would gap [Baidu] in a position where they could immediately apply their technology to the real world."
- Of note: Baidu has never acquired a major foreign software company, never mind one with an enterprise value above $6B. In addition, regulators might closely scrutinize any attempt by a Chinese company to buy Nuance.
- Nuance has turned positive after previously following equity markets lower. Shares slumped on Friday thanks to a Goldman downgrade.
Fri, Jan. 9, 9:25 AM
- "We do not see NUAN as a potential acquisition candidate, and see growth and margins challenged," writes Goldman's Greg Dunham, downgrading the voice recognition software/services giant to Sell.
- Goldman's LBO model suggests a -1% IRR for a Nuance LBO under its base-case scenario, compared with a 20% IRR for enterprise software vendors CommVault and Informatica.
- The WSJ reported back in June Nuance had talked with Samsung and P-E firms about a potential sale. Speculation that Carl Icahn would push the company to sell itself has been around for some time.
- Shares have made new 52-week lows. They now go for ~3x estimated FY15 (ends Sep. '15) EV/sales.
Dec. 15, 2014, 7:54 AM
- The Q-50 Index houses those companies next-eligible for inclusion into the Nasdaq 100 (NASDAQ:QQQ). Amid the Nasdaq 100's annual changes which added and dropped three from the index, the Q-50's quarterly re-ranking adds and drops eleven.
- Added: Ainylam Pharma (NASDAQ:ALNY), Expedia (NASDAQ:EXPE), F5 Networks (NASDAQ:FFIV), JD.com (NASDAQ:JD), MercadoLibre (NASDAQ:MELI), Maxim Integrated (NASDAQ:MXIM), Old Dominion Freight Line (NASDAQ:ODFL), Shire (NASDAQ:SHPG), Splunk (NASDAQ:SPLK), Stratasys (NASDAQ:SSYS), United Therapeutics (NASDAQ:UTHR).
- Dropped: Avis Budget (NASDAQ:CAR), Cree (NASDAQ:CREE), First Solar (NASDAQ:FSLR), Golar LNG (NASDAQ:GLNG), Methanex (NASDAQ:MEOH), Melco Crown (NASDAQ:MPEL), Nuance (NASDAQ:NUAN), SolarCity (NASDAQ:SCTY). Also dropped are the three Nasdaq 100 additions: American Airlines, Lam Research, and Electronic Arts.
- Source: Press Release
- Previously: Who's in, who's out in annual change to Nasdaq 100 (Dec. 13, 2014)
Nov. 25, 2014, 9:15 AM
Nov. 24, 2014, 5:43 PM
Nov. 24, 2014, 4:22 PM
- Nuance (NASDAQ:NUAN) guides in its prepared remarks (.pdf) for FQ1 revenue of $480M-$490M and EPS of $0.21-$0.23, below a consensus of $500.6M and $0.27. FY15 (ends Sep. '15) guidance is healthier: Revenue of $2.02B-$2.08B and EPS of $1.10-$1.20 vs. a consensus of $2.07B and $1.15.
- Bookings rose 24.5% Y/Y in FQ4 to $497.7M, an improvement from FQ3's 16.7% growth. FY14 bookings totaled $2.44B, +27.4% Y/Y and above guidance of $2.35B-$2.4B. 6%-8% net new bookings growth is expected in FY15.
- Healthcare revenue (responsible for nearly half of all op. profit) +3% Y/Y to $238.3M; mobile & consumer -3% to $116.9M; enterprise -4% to $95.6M; imaging +9% to $69.5M.
- Healthcare growth improved from FQ3's -2% thanks to on-demand, diagnostics, and Clintegrity sales. Mobile & consumer benefited from auto growth, and was hurt by weak phone-related sales. Though enterprise revenue is soft, bookings (boosted by Nina) are healthier.
- No buybacks took place in FQ4. GAAP opex rose 5% Y/Y to $282.2M. Thanks to a shift towards subscriptions/recurring revenue streams, Nuance's deferred revenue balance rose 32% Y/Y to $548.1M.
- FQ4 results, PR
Nov. 24, 2014, 4:04 PM| Comment!
NUAN vs. ETF Alternatives
Other News & PR